Topical pimecrolimus for skin disease other than atopic dermatitis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1967-1975

  Wollina, Uwe ^a   Hansel, Gesina ^a   Koch, André ^a   Abdel Naser, Mohamed Badawy ^b  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b Ain Shams University Hospital   (Egypt)

Author keywords

Calcineurin inhibitor; Inflammatory skin diseases; Pimecrolimus; Topical pimecrolimus

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; ASCOMYCIN; AZELAIC ACID; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLINDAMYCIN; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; METRONIDAZOLE; PIMECROLIMUS; PLACEBO; PSORALEN; RETINOID; STEROID; TACROLIMUS; TETRACYCLINE; THALIDOMIDE; TRANILAST; VITAMIN D DERIVATIVE;

ACNE VULGARIS; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; BALANITIS; BURNING SENSATION; CELL ACTIVATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; CREAM; CRYOSURGERY; DISCOID LUPUS ERYTHEMATOSUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG FORMULATION; ERYTHEMA; EVIDENCE BASED MEDICINE; FOLLICULITIS; GENITAL HERPES; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HAND ECZEMA; HUMAN; IRRITANT DERMATITIS; LICHEN AUREUS; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; LICHEN STRIATUS; LIPOPHILICITY; LOW LEVEL LASER THERAPY; LYMPHOMA; MAST CELL; MASTOCYTOSIS; NETHERTON DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PLASMACYTOSIS; PRURITUS; PSORIASIS; RISK REDUCTION; ROSACEA; SEBORRHEIC DERMATITIS; SKIN ALLERGY; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; SKIN IRRITATION; SKIN LUPUS ERYTHEMATOSUS; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA; TERATOGENICITY; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION; VITILIGO; VULVITIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SKIN DISEASES; TACROLIMUS; TREATMENT OUTCOME;

EID: 33749361700     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1967     Document Type: Article

References (67)

1. GUPTA AK, CHOW M: Pimecrolimus: a review. J. Eur. Acad. Dermatol. Venereol. (2003) 17:493-503.
2. WOLFF K, STUETZ A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5:643-655.
3. DRAELOS Z, NAYAK A, PARISER D et al: Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J. Am. Acad. Dermatol. (2005) 53:602-609.
4. MEINGASSNER JG, ASCHAUER H, STUETZ A, BLILLICH A: Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp. Dermatol. (2005) 14:752-757.
5. PAUL C, CORK M, ROSSI AB, PAPP KA, BARBIER N, DE FROST Y: Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated up to 2 years. Pediatrics. (2006) 117:118-125.
6. SUNDERKÖTTER C, WEISS JM, BEXTERMÖLLER R, LÖFFLER H, SCHNEIDER D: Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: Positive effects on major symptoms of atopic dermatitis and quality of life. J. Dtsch. Dermatol. Ges. (2006) 4:301-306.
7. LUGER T, LAHFA M, FOLSTER-HOLST R et al.: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatol. Treat. (2004) 15:169-178.
8. FONACIER L, SPERGEL J, CHARLESWORTH EN et al.: Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. (2005) 115:1249-1253.
9. YAROSH DB, PENA AV, NAY SL, CANNING MT, BROWN DA: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol. (2005) 125:1220-1025.
10. TRAN C, LUBBE J, SORG O et al.: Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology (2005) 211:341-347.
11. DOELKER L, TRAN C, GKOMOUZAS A et al.: Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp. Dermatol. (2006) 15:342-346.
12. RING J, BARKER J, BEHRENDT H et al.: Review of the potential photo-cocarcinogenecity of topical calcineurin inhibitors. Position statement of the European Dermatology Forum. J. Eur. Acad. Dermatol. Venereol. (2005) 19:663-671.
13. BERGER TG, DUVIC M, VAN VOORHEES AS, FRIEDEN IJ: The use of topical calcineurin inhibitors in dermatology; safety concerns. Report of the American Academy of Dermatology Association Task Force. J. Am. Acad. Dermatol. (2006) 54:818-823.
14. CRUTCHFIELD CE III: Pimecrolimus: new treatment for seborrheic dermatitis. Cutis (2002) 70:207-208.
15. BROWNELL I, QUAN LT, HSU S: Topical pimecrolimus in the treatment of seborrhoic dermatitis. Dermatology Online J. (2003) 9:13.
16. RALLIS E, NASIOPOULOU A, KOUSKOUKIS C, KOUMANTAKI E: Pimecrolimus cream 1% can be an effective treatment for seborrheic dermatitis of the face and trunk. Drugs Exp. Clin. Res. (2004) 30:191-195.
17. RIGOPOULOS D, IOANNIDES D, KALOGEROMITROS D, GREGORIOU S, KATSAMBAS A: Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical study. Br. J. Dermatol. (2004) 151:1071-1075.
18. HIGH WA, PANDYA AG: Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J. Am. Acad. Dermatol. (2006) 54:1083-1088.
19. BLACK RJ: Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin. Exp. Dermatol. (2005) 30:91-92.
20. BELSITO DV, FOWLER JF Jr, MARKS JG Jr et al.: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis (2004) 73:31-38.
21. WARSHAW EM: Therapeutic options for chronic hand dermatitis. Dermatol. Therapy (2004) 17:240-250.
22. COHEN DE, HEIDARY N: Treatment of irritant and allergic contact dermatitis. Dermatol. Therapy (2004) 17:334-340.
23. WOLLINA U, ABDEL-NASER MB: Pharmacotherapy of pompholyx. Exp. Opin. Pharmacother. (2004) 5:1517-1522.
24. BUKHARI IA: Successful treatment of chronic persistant vesicular hand dermatitis with topical pimecrolimus. Saudi Med. J. (2005) 26:1989-1991.
25. BRUCKNERAL, WESTON WL: Allergic contact dermatitis in children: a practical approach to management. Skin Therapy Lett. (2002) 7:3-5.
26. KREUTER A, HOCHDORFER B, ALTMEYER P, GAMBICHLER T: Pimecrolimus 1% cream for perianal atopic dermatitis. Br. J. Dermatol. (2005) 152:186-187.
27. LAZAROUS MC, KERDEL FA: Topical tacrolimus Protopic. Drugs Today (2002) 38:7-15.
28. MROWIETZ U, GRAEBER M, BRÄUTIGAM M et al.: The novel ascomycin derivate SDZ ASM 981 is effective in psoriasis when used topically under occlusion. Br. J. Dermatol. (1998) 139:992-996.
29. GRIBETZ C, LING M, LEBWOHL M et al.: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. (2004) 51:731-738.
30. LEWKOWICZ D, GOTTLIEB AB: Pediatric psoriasis and psoriatic arthritis. Dermatol Therapy (2004) 17:364-375.
31. AMICHAI B: Psoriasis of the glans penis in a child successfully treated with Elidel® (pimecrolimus) cream. J. Eur. Acad. Dermatol. Venereol. (2004) 18:742-743.
32. TAN JKL, MORNEAU K, FUNG K: Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J. Am. Acad. Dermatol. (2005) 52:738-739.
33. BARR J, FRIEDMAN A: Use of imiquimod and pimecrolimus cream in the treatment of acne keloidalis nuchae. J. Am. Acad. Dermatol. (2005) 52:P64.
34. CRAWFORD KM, RUSS B, BOSTROM P: Pimecrolimus for treatment of acne rosacea. Skinmed (2005) 4:147-150.
35. CHU C-Y: The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br. J. Dermatol. (2005) 152:396-399.
36. GORMAN CR, WHITE SW: Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch. Dermatol. (2005) 141:1168.
37. ZABAWSKI E: Treatment of cutaneous lupus with Elidel™. Dermatology Online J. (2002) 8:25.
38. TLACUILO-PARRA A, GUEVARA-GUTIERREZ E, GUTIERREZ-MURILLO F et al.: Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (2005) 44:1564-1568.
39. KREUTER A, GAMBICHLER T, BREUCKMANN F et al.: Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. (2004) 51:407-410.
40. ALMEIDA HL Jr, OLIVEIRA FILHO UL: Topical pimecrolimus is an effective treatment for balanitis circinata erosive. Int. J. Dermatol. (2005) 44:888-889.
41. DAVATCHI F: New and innovative therapies for Behcet's disease. APLAR J. Rheumatol. (2004) 7:141-145.
42. LIM SJ, LOVE EW: Steroid-free pimecrolimus (Elidel) for monotherapy of lichen planus. J. Drugs Dermatol. (2004) 3:563-564.
43. LONSDALE-ECCLES AA, VELANGI S: Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br. J. Dermatol. (2005) 153:390-394.
44. ESQUIVEL-PEDRAZA L, FERNÁNDEZ-CUEVAS L, ORTIZ-PEDROZA G, REYES-GUTIÉRREZ E, OROZCO-TOPETE R: Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br. J. Dermatol. (2004) 150:771-773.
45. MATTSSON U, JONTELL M, HOLMSTRUP P: Oral lichen planus and malignant transformation: is a recall of patients justified? Crit. Rev. Oral Biol. Med. (2002) 13:390-396.
46. GOLDSTEIN AT, MARINOFF SC, CHRISTOPHER K: Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases. J. Reprod. Med. (2004) 49:778-780.
47. ARICAN O, CIRALIK H, SASMAZ S: Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J. Dermatol. (2004) 31:1014-1017.
48. BOMS S, GAMBICHLER T, FREITAG M, ALTMEYER P, KREUTER A: Pimecrolimus 1% cream for anogenital lichen sclerosus in childhood. BMC Dermatology (2004) 4:14.
49. GOLDSTEIN AT, MARINOFF SC, CHRISTOPHER K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J. Pediatr. Adolesc. Gynecol. (2004) 17:35-37.
50. GRIMES PE: New insights and new therapies in vitiligo. JAMA (2005) 293:730-735.
51. COSKUN B, SARAL Y, TURGUT D: Topical 0.05% cloberasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur. J. Dermatol. (2005) 15:88-91.
52. OSTOVARI N, PASSERON T, LACOUR JP, ORTONNE JP: Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch. Dermatol. (2006) 142:252-253.
53. OJI V, BELJAN G, BEIER K, TRAUPE H, LUGER TA: Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br. J. Dermatol. (2005) 153:1067-1068.
54. THACI D, PÄTZOLD S, SCHWANNER S, SPIETH K, RUNNE U, KAUFMANN R: Comel-Netherton syndrome: a case treated with topical pimecrolimus cream 1%. J. Eur. Acad. Dermatol. Venereol. (2004) 18(Suppl 2):160-161.
55. SCHMOOK T, KRAFT J, BENNINGHOFF B, et al.: Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant. (2005) 36:87-88.
56. ZIEMER M, GRUHN M, THIELE JJ, ELSNER P: Treatment of extensive chronic cutaneous graft-versus-hoist disease in an infant with topical pimecrolimus. J. Am. Acad. Dermatol. (2004) 50:946-948.
57. NEUMAN DL, FARRAR JE, MORESI JM, VOGELSANG GB, HIGMAN MA: Toxic absorption of pimecrolimus in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant. (2005) 36:919-920.
58. KUS S, INCE U: Lichen striatus in an adult patient treated with pimecrolimus. J. Eur. Acad. Dermatol. Venereol. (2006) 20:341-362.
59. ALMEIDA HL Jr: Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int. J. Dermatol. (2005) 44:343-344.
60. LEE HW, JEONG YI, CHOI JC et al.: Two cases of teleangiectasia macularis eruptive persrans demonstrated by immunohistochemistry for c-kit (CD 117). J. Dermatol. (2005) 32:817-820.
61. ALMEIDA HL Jr: Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J. Am. Acad. Dermatol. (2005) 53:357-358.
62. SULI DJ, HARFORD R, O'NEILL JT: Discrete popular form of lichen myxedematosus: a case report and review of the literature. Cutis. (2005) 75:105-112.
63. BÖHM M, BONSMANN G, LUGER TA: Resolution of lichen aureusin a 10-year-old child after topical pimecrolimus. Br. J. Dermatol. (2004) 150:519-520.
64. RIGOPOULOS D, PRANTSIDIS A, CHRISTOFIDOU E, IOANNIDES D, GREGORIOU S, KATSAMBAS A: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br. J. Dermatol. (2005) 152:1364-1365.
65. LEE HW, LEE MW, CHOI JH, MOON KC, KOH JK: Annular elastolytic giant cell granuloma in an infant: improvement after treatment with oral transilast and topical pimecrolimus. J. Am. Acad. Dermatol. (2005) 53(Suppl. 2):S244-S246.
66. HAFNER C, HOHENLEUTNER U, BABILAS P, LANDTHALER M, VOGT T: Targeting T cells to hit B cells: successful treatment of cutaneous plasmacytosis with topical pimecrolimus. Dermatology (2006) 213:163-165.
67. SACKETT DL, ROSENBERG WM: The need for evidence-based medicine. J. R. Soc. Med. (1995) 88:620-624.